Litcius/Paper detail

Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial

Mahir Karakas, İbrahim Akın, Christoph Burdelski, Peter Clemmensen, Hanno Grahn, Dominik Jarczak, Mirjam Keßler, Paulus Kirchhof, Ulf Landmesser, Susanne Lezius, Diana Lindner, Alexandre Mebazaa, Axel Nierhaus, Anil Ocak, Wolfgang Rottbauer, Christoph Sinning, Carsten Skurk, Gerold Söffker, Dirk Westermann, Antonia Zapf, Elvin Zengin, Tanja Zeller, Stefan Kluge

2021The Lancet Respiratory Medicine37 citationsDOI

Topics & Concepts

MedicineCardiogenic shockPlaceboDouble blindedShock (circulatory)Physical therapyAnesthesiaInternal medicineMyocardial infarctionAlternative medicinePathologyNeuropeptides and Animal PhysiologySepsis Diagnosis and TreatmentHeparin-Induced Thrombocytopenia and Thrombosis
Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial | Litcius